Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary

Ensysce Biosciences (NASDAQ:ENSC) announced it will host a symposium at the IASP 2024 World Congress on Pain on August 8, 2024, in Amsterdam. The symposium titled 'Severe Pain: A New Chapter for Safer Analgesics' will feature Dr. Lars Arendt-Nielsen and Dr. William Schmidt, who will discuss the landscape of severe pain treatment, trends in treatment, and the safety and effectiveness of Ensysce's PF614 and PF614-MPAR based on clinical data. CEO Dr. Lynn Kirkpatrick emphasized the importance of the event for presenting their technology platforms, TAAP and MPAR, which aim to reduce prescription drug abuse and overdose.

  • Ensysce will host a symposium at a major international conference, increasing visibility and credibility.
  • Clinical data on PF614 and PF614-MPAR will be presented, highlighting their safety and effectiveness.
  • Participation by leading pain treatment authorities, potentially boosting confidence in Ensysce's solutions.
  • No direct mention of commercialization timelines for PF614 and PF614-MPAR, which could concern investors.

~ Dr. Lynn Kirkpatrick, CEO, to Introduce Satellite Symposium on Severe Pain: A New Chapter for Safer Analgesics ~

SAN DIEGO, CA / ACCESSWIRE / July 9, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that the Company will host a symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain on August 8, 2024 in Amsterdam, Netherlands. The Symposium entitled: ‘Severe Pain: A New Chapter for Safer Analgesics' will feature Dr. Lars Arendt-Nielsen, Professor of Aalberg University of Medicine, Denmark, and Dr. William Schmidt, Chief Medical Officer of Ensysce Biosciences, two leading authorities on pain, pain treatment and analgesic drug development.

Overall objectives of the session are to understand the current landscape for acute and severe pain treatment. Speakers will discuss current trends in severe pain associated with surgery and cancer progression, review drug use and abuse, and then examine the safety and effectiveness of PF614 and PF614-MPAR as indicated by clinical data results and how the leading agents are positioned for future clinical study.

Dr. Lynn Kirkpatrick, CEO of Ensysce, commented, "Our team is pleased to be participating in this leading forum that is instrumental in providing a broad understanding and treatment of pain. Further, we are honored to have been selected to present the clinical data of our technology platforms Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR®) in this distinct IASP symposium and explain how our unique approach protects against prescription drug abuse and oral overdose. It is gratifying that world renowned experts on the treatment of severe pain believe we have promising new products soon to enter this market. The IASP Conference is where we can immerse ourselves in this world of clinicians and interact with leaders in our field."

IASP has a mission to deliver pain relief throughout the world. It is the leading conference dedicated to helping pain physicians and practitioners improve their clinical knowledge to help patients. Please find more information at the IASP website:

About Ensysce Biosciences

Ensysce Biosciences is a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit

Forward-Looking Statements

Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC's website at Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.

Ensysce Biosciences Company Contact:

Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196

Ensysce Biosciences Investor Relations Contact:

Shannon Devine
MZ North America
Main: 203-741-8811

SOURCE: Ensysce Biosciences Inc.

View the original press release on


When and where is Ensysce Biosciences hosting its symposium?

On August 8, 2024, at the IASP 2024 World Congress on Pain in Amsterdam, Netherlands.

What is the focus of Ensysce Biosciences' symposium at IASP 2024?

The focus is on 'Severe Pain: A New Chapter for Safer Analgesics,' discussing trends in severe pain treatment and the safety and effectiveness of PF614 and PF614-MPAR.

Who are the key speakers at Ensysce Biosciences' symposium?

Dr. Lars Arendt-Nielsen from Aalberg University and Dr. William Schmidt, Chief Medical Officer of Ensysce Biosciences.

What technologies will Ensysce Biosciences present at the symposium?

They will present the Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms.

What is the stock symbol for Ensysce Biosciences?

The stock symbol for Ensysce Biosciences is ENSC.

Ensysce Biosciences, Inc.


ENSC Rankings

ENSC Latest News

ENSC Stock Data

Pharmaceutical Preparation Manufacturing
United States of America